(Q45735357)

English

Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era.

scientific article published on 10 October 2001

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

0 references

1 reference

based on heuristic

inferred from title

Dominique Costagliola

object named as

D Costagliola

3

0 references

author name string

S Abgrall

1

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

C Rabaud

2

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Clinical Epidemiology Group of the French Hospital Database on HIV

4

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

language of work or name

0 references

publication date

10 October 2001

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

1747-1755

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Toxoplasmic encephalitis in AIDS.

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995. HEMOCO and SEROCO Study Groups

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Survivor treatment selection bias in observational studies: examples from the AIDS literature

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Rapid disease progression in human immunodeficiency virus type 1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis.

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients.

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis

1 reference

https://api.crossref.org/works/10.1086%2F322622

21 January 2018

Identifiers

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45735357&oldid=1586625491"